Study Finds Maternal RSV Vaccine Not Likely To Increase Risks Of Preterm Birth

Pfizer’s vaccine for respiratory syncytial virus (RSV) in pregnant people, intended to prevent severe cases of the virus in infants, is likely not associated with a risk of preterm birth despite initial FDA concerns, according to a study that could boost uptake of the vaccine. A commentary on the topic was published in the journal JAMA Network Open July 8 by Annette Regan, a professor at the University of San Francisco School of Nursing and Health Professions. It responded...